key: cord-0728014-50pd16fy
authors: Fan, Bingwen Eugene; Umapathi, Thirugnanam; Chua, Karen; Chia, Yew Woon; Wong, Shiun Woei; Tan, Glenn Wei Leong; Chandrasekar, Sadhana; Lum, Ying Hui; Vasoo, Shawn; Dalan, Rinkoo
title: Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients
date: 2020-11-07
journal: J Thromb Thrombolysis
DOI: 10.1007/s11239-020-02332-z
sha: 635fd1d98bc7faf3da9c4abfc74391bf5fedd49e
doc_id: 728014
cord_uid: 50pd16fy

nan

We read with interest the editorial "Anticipating the longterm cardiovascular effects of COVID-19 [1] " which featured COVID-19 end-organ thrombotic complications. COVID-19 associated hypercoagulability [2] and increased thromboembolism in COVID-19 has been well described [3] . While the editorial raised the key question about "potential long-term cardiovascular effects (of COVID-19)", little is known about the post COVID-19 vascular complications. In response, we would like to highlight a series of catastrophic arterial events observed in post COVID-19 patients (Table 1) , echoing the Editor's concerns of post-infectious vasculopathy.

During the months of April 2020 to July 2020, Singapore experienced a surge in COVID-19 cases amongst our migrant workers. Subsequently, in July 2020 to September 2020, 4 young healthy migrant workers presented with catastrophic, large arterial thromboses. They were detected to have COVID-19 during routine screening of affected migrant workers' dormitories. They had raised Immunoglobulin G for SARS-CoV-2 (Roche Elecsys Anti-SARS-CoV-2) indicative of COVID-19 seroconversion. They were asymptomatic and did not meet criteria necessitating hospitalization nor thromboprophylaxis and were quarantined at isolation facilities. Subsequently, they presented with a sentinel thrombotic event at a median of 78 days from seroconversion. Their median age was 38.5 years, and they were of South Asian ethnicity. Cardiovascular risk factors screening showed that one had recently diagnosed diabetes mellitus with a HbA1c of 6.7% whilst the others did not have any risk factors.

Two patients suffered from severe large vessel ischaemic strokes ( Fig. 1a-d) , one had an acute ischaemic limb ( Fig. 2a) due to emboli from an aortic thrombosis (Fig. 2b) , and one had anterolateral ST-Elevation Myocardial Infarction ( Fig. 3a-c) . No features of overt arteriosclerotic disease were found during neuroimaging, CT angiography and coronary angiography. Thrombophilia screen and stroke evaluation inclusive of carotid imaging, echocardiography, 24-h holter monitoring were normal.

The remarkable features of these cases include young age without preexisting cardiovascular risk factors, asymptomatic SARS-CoV-2 infection and the long latency between initial positive serology and their catastrophic vascular event. Firstly, two patients had an unusual site of thrombosis, with mobile aortic thromboses discovered on CT imaging. Aortic thrombosis is rare in young patients without a significant thromboembolic risk factors or pre-existing arteriosclerosis. The SARS-CoV-2 virus is known to cause endothelial damage during acute infection [4, 5] and cases of COVID-19 associated acute ischaemic limb secondary to embolism from aortic thrombosis have been described [6, 7] . However, less is known about persistence of endotheliitis in the convalescent phase of illness. We postulate that post SARS-CoV-2 infection, a state of endothelial activation with downstream signaling pathways of low-grade inflammation and thrombosis may persist [8] . Similar mural thrombosis has been described in patients on chemotherapy and has been attributed to trauma to vascular endothelium and a hypercoagulable state [9] . However, our patients did not consume any medications and did not have any endovascular lines. The aortic thrombosis in COVID-19 could be a consequence of persistent endothelial dysfunction due to viral inclusion bodies at specific sites (this has been reported in Chilblains ('COVID toes') in children and young adults [10] ) Secondly, haemostatic assessment of the 4 patients at time of acute thrombosis highly suggested a hypercoagulable state, with a markedly raised Factor VIII, elevated von Willebrand factor antigen, increased D-dimer levels and hyperfibrinogenaemia. Both endothelial dysfunction and hypercoagulability are 2 key factors in Virchow's triad for thrombosis. The post-thrombosis evaluation of the haemostatic profile in 2 of our patients with ischaemic stroke at a 2 to 3-month window from onset of acute stroke revealed declining but persistently raised von Willebrand factor antigen, Factor VIII, and fibrinogen levels. A persistently raised von Willebrand factor may reflect chronic endothelial activation and dysfunction [11] , as well as ongoing platelet hyperactivation [12] . Thirdly, for the young patient with cardiac arrest and acute myocardial infarction, COVID-19 may have induced an 'accelerated atherosclerosis' and precipitated a coronary event during his convalescence. There was complete occlusion of left anterior descending (LAD) artery (Fig. 3a) . This is suggested by findings from Intravascular ultrasound (Volcano Eagle Eye catheter) which was used to interrogate the LAD artery. Small amount of clot was retrieved using thrombectomy device. It showed a focal heavily fibrous plaque burden of 59% and minimal lumen diameter of 2.1 mm in the ostial LAD (Fig. 3c) , with a plaque burden of more than 70% and patient (a, b) , and M1 segment of left middle cerebral artery in the second patient (c, d) minimal lumen area of less than 4mm 2 being independent predictors of major adverse cardiovascular events [13] . This is unusual as fibrotic lesions are usually deprived from lipid and inflammatory cells and hence less likely to rupture and generate thrombosis [14] . COVID-19 is known to cause cardiac complications with a case series from China reporting a high percentage (19.7%) of COVID 19 patients having evidence of myocardial injury with 51% in-hospital mortality compared with 4.5% without raised troponin [15] . Potential mechanisms that explain cardiac injury during acute infection include (i) imbalance in myocardial demand and supply due to tachycardia and hypotension from type 2 myocardial infarction; (ii) acute atherothrombosis in a virally induced thrombotic and inflammatory milieu; (iii) microvascular dysfunction from microthrombi or endothelial injury; (iv) stress-related cardiomyopathy (Takotsubo) and (v) direct cardiomyocyte toxicity and myocarditis, of which artherothrombosis as well as direct cardiomyocyte toxicity may cause sustained longterm damage to the coronary vessels and the myocardium, with 10 patients in Germany critically ill with COVID-19 demonstrating low to no detectable virus in myocardial tissues despite multiple microemboli in the heart [16] . These observations suggest that the SARS-CoV-2 virus poses significant and chronic immuno-thrombogenicity which may cumulate eventually in a major thrombotic event.

Although small, our case series suggests that catastrophic vascular events can occur unexpectedly in fit patients with mild or asymptomatic COVID-19 infection and may unpredictably happen many weeks later.

The COVID-19 pandemic has a prolonged and serious impact on the cardiovascular health of patients. Hence for c Intravascular ultrasound (virtual histology) showed predominantly fibrotic plaque with minimal necrotic core in the ostial LAD convalescent patients, regardless of the severity of infection and the absence of co-morbidities, clinicians should remain vigilant for post-infective thrombotic sequelae as well as consider screening for and closely managing cardiovascular risk factors. Multi-disciplinary collaboration into the epidemiology, pathogenesis and treatment of COVID-19 associated thrombosis and in evaluating the utility of extended thromboprophylaxis for COVID-19 patients should be strongly considered.

Author contributions BEF and RD conceived the manuscript. All authors made substantial contributions in analysing the data, revising it critically for important intellectual content and editing the manuscript.

Funding No funding for this study was obtained. All authors had full access to the full data in the study and accept responsibility to submit for publication.

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval A waiver of informed consent was provided by the Ministry of Health (Singapore), under the provisions of the Infectious Diseases Act.

Anticipating the long-term cardiovascular effects of COVID-19

COVID-19 associated coagulopathy in critically ill patients: a hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Endothelial cell infection and endotheliitis in COVID-19

COVID-19-associated vasculitis and vasculopathy

Acute aortic thrombosis presenting as acute limb ischemia in two young, non-atherosclerotic patients

Global haemostatic tests in rapid diagnosis and management of COVID-19 associated coagulopathy in acute limb ischaemia

The implications of COVID-19 infection on the endothelium: a metabolic vascular perspective. Diabetes

Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group

SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a singlecentre, cross-sectional study

Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19

Thinking outside the lumen: fractional flow reserve versus intravascular imaging for major adverse cardiac event prediction

Multimodality intravascular imaging to evaluate sex difference in plaque morphology in stable CAD

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan China

Microthrombic and ST-segment elevation myocardial infarction in COVID-10